DCF Advisers, LLC - Q1 2023 holdings

$163 Million is the total value of DCF Advisers, LLC's 67 reported holdings in Q1 2023. The portfolio turnover from Q4 2022 to Q1 2023 was - .

 Value Shares↓ Weighting
AMGN NewAMGEN INC$2,417,50010,000
+100.0%
1.48%
TPB NewTURNING PT BRANDS INC$1,745,37083,113
+100.0%
1.07%
NewESPERION THERAPEUTICS INC NEnote 4.000%11/1$1,476,0003,600,000
+100.0%
0.90%
BIIB NewBIOGEN INC$1,362,3504,900
+100.0%
0.83%
AMGN NewAMGEN INCcall$1,063,7004,400
+100.0%
0.65%
MU NewMICRON TECHNOLOGY INCput$603,40010,000
+100.0%
0.37%
INTC NewINTEL CORP$571,73017,500
+100.0%
0.35%
AMZN NewAMAZON COM INC$516,4505,000
+100.0%
0.32%
EEM NewISHARES TRmsci emg mkt etf$493,00012,500
+100.0%
0.30%
BA NewBOEING CO$477,9702,250
+100.0%
0.29%
C NewCITIGROUP INC$339,9507,250
+100.0%
0.21%
EOG NewEOG RES INC$275,1102,400
+100.0%
0.17%
SPOT NewSPOTIFY TECHNOLOGY S A$267,2402,000
+100.0%
0.16%
OI NewO-I GLASS INC$261,17011,500
+100.0%
0.16%
SBUX NewSTARBUCKS CORP$208,2602,000
+100.0%
0.13%
EVTCY NewEVOTEC AGsponsored ads$129,46012,388
+100.0%
0.08%
UNG NewUNITED STS NAT GAS FD LPunit par$104,10015,000
+100.0%
0.06%
Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR filed 2023-05-15
Signatures

The EDGAR filing(s) were signed by:

Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
INTRA-CELLULAR THERAPIES INC16Q3 202310.2%
MICRON TECHNOLOGY INC16Q3 20236.7%
ALPHABET INC16Q3 20235.8%
ABBVIE INC16Q3 20237.9%
REGENERON PHARMACEUTICALS16Q3 20235.5%
ARGENX SE16Q3 20236.4%
SPDR GOLD TRUST16Q3 20236.6%
XENCOR INC16Q3 20234.1%
BK OF AMERICA CORP16Q3 20235.4%
ORACLE CORP16Q3 20233.2%

View DCF Advisers, LLC's complete holdings history.

Latest filings
TypeFiled
13F-HR2024-02-13
13F-HR2023-11-13
13F-HR2023-08-09
13F-HR2023-05-15
13F-HR2023-02-13
13F-HR2022-11-14
13F-HR2022-08-11
13F-HR2022-05-13
13F-HR2022-02-10
13F-HR2021-11-15

View DCF Advisers, LLC's complete filings history.

Compare quarters

Export DCF Advisers, LLC's holdings